$EVFM
Evofem Biosciences, Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016028810 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.060M $910.0K
YoY Change -51.82% -48.59%
% of Gross Profit
Research & Development $930.0K $960.0K
YoY Change -86.77% -93.69%
% of Gross Profit
Depreciation & Amortization $20.00K $10.00K
YoY Change 0.0% -50.0%
% of Gross Profit
Operating Expenses $1.980M $1.870M
YoY Change -78.55% -88.99%
Operating Profit
YoY Change
Interest Expense $10.00K -$490.0K
YoY Change -103.57% 75.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.970M -$2.360M
YoY Change -79.31% -86.33%
Income Tax
% Of Pretax Income
Net Earnings -$1.970M -$2.360M
YoY Change -79.31% -86.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$852.8K -$1.026M
COMMON SHARES
Basic Shares Outstanding 13.83M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.50M $14.40M
YoY Change -69.5% -71.93%
Cash & Equivalents $11.68M $14.36M
Short-Term Investments
Other Short-Term Assets $1.000M $500.0K
YoY Change -50.0% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.50M $14.90M
YoY Change -68.53% -71.51%
LONG-TERM ASSETS
Property, Plant & Equipment $109.3K $100.0K
YoY Change -41.34% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $316.7K $300.0K
YoY Change -18.03% -25.0%
TOTAL ASSETS
Total Short-Term Assets $12.50M $14.90M
Total Long-Term Assets $316.7K $300.0K
Total Assets $12.82M $15.20M
YoY Change -68.05% -71.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $503.7K $800.0K
YoY Change -87.46% -87.5%
Accrued Expenses $398.5K $600.0K
YoY Change -82.68% -83.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $902.2K $1.400M
YoY Change -90.09% -88.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $902.2K $1.400M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $900.0K $1.400M
YoY Change -94.48% -92.96%
SHAREHOLDERS EQUITY
Retained Earnings -$125.9M -$123.9M
YoY Change 11.54% 19.9%
Common Stock $137.8M $137.7M
YoY Change 0.82% 1.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$181.1M $13.77M
YoY Change
Total Liabilities & Shareholders Equity $12.82M $15.21M
YoY Change -68.05% -71.13%

Cashflow Statement

Concept 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$1.970M -$2.360M
YoY Change -79.31% -86.33%
Depreciation, Depletion And Amortization $20.00K $10.00K
YoY Change 0.0% -50.0%
Cash From Operating Activities -$2.880M -$3.130M
YoY Change -78.78% -73.32%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -3.990M
YoY Change -100.0% -10075.0%
NET CHANGE
Cash From Operating Activities -2.880M -3.130M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 -3.990M
Net Change In Cash -2.880M -7.120M
YoY Change -78.68% -39.09%
FREE CASH FLOW
Cash From Operating Activities -$2.880M -$3.130M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.880M -$3.130M
YoY Change -78.78% -73.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13828496
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37748603
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1976997
CY2015Q4 us-gaap Assets Current
AssetsCurrent
39725600
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
200000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Trading Symbol
TradingSymbol
NEOT
dei Entity Registrant Name
EntityRegistrantName
Neothetics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001618835
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
186372
CY2015Q4 us-gaap Assets
Assets
40111972
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4017192
CY2015Q4 neot Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
1422810
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
1382
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
137651010
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123878282
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
13774110
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15205833
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13828496
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13828496
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13365846
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
226128
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-426128
us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
9514058
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
485942
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
52400
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33542
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
19090
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-10018858
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-23384704
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75947516
us-gaap Interest Paid
InterestPaid
664292
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></div>
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.43
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.</p></div>
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.52
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.63
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1262170
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1580929
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
71257
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1363027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
563856
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
78480
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
657490
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1190913
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.09
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
83018
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
365986
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
970381
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1042014
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1956369
CY2016Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3654714
neot Noncancelable Operating Lease Agreement Date
NoncancelableOperatingLeaseAgreementDate
2015-01-20
neot Lease Expiration Period
LeaseExpirationPeriod
2020-03
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
95631
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
395520
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
410850
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
431508
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
109293
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1442802

Files In Submission

Name View Source Status
0001564590-16-028810-index-headers.html Edgar Link pending
0001564590-16-028810-index.html Edgar Link pending
0001564590-16-028810.txt Edgar Link pending
0001564590-16-028810-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
neot-10q_20160930.htm Edgar Link pending
neot-20160930.xml Edgar Link completed
neot-20160930.xsd Edgar Link pending
neot-20160930_cal.xml Edgar Link unprocessable
neot-20160930_def.xml Edgar Link unprocessable
neot-20160930_lab.xml Edgar Link unprocessable
neot-20160930_pre.xml Edgar Link unprocessable
neot-ex311_7.htm Edgar Link pending
neot-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending